Moderna Stock News

Moderna (MRNA) closed at $100.35 in the latest trading session, marking a -1.77% move from the prior day.

With so many question marks facing the viability of the equities sector, concerned investors may want to turn their attention to compelling healthcare stocks. Primarily, the sector benefits from perma

Plug Power's financials are in horrible shape, and a lack of cash is a big concern for investors. Moderna's reliance on COVID and flu revenue could limit any growth it's able to generate ahead.

While the technology sector – especially regarding artificial intelligence – may have captured the spotlight, investors ought to consider adding healthcare stocks to their portfolio. If I had to b

Owning powerhouse stocks can add significant value to your portfolio. Megatrends are those that are shaping or will shape society in significant ways.

The latest trading day saw Moderna (MRNA) settling at $109.46, representing a -0.65% change from its previous close.

Today, identifying investments with promising growth potential is a quest every investor undertakes. Within the loud noises of the stock market, three standout companies are making waves.

Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.

The S&P 500 is within striking distance of entering official bull market territory. To qualify, the index would need to rise more than 20% from its previous low and hit a new all-time high.

Moderna, Inc. (MRNA) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript

Metagenomi Technologies, a startup developing treatments for genetic diseases backed by Moderna Therapeutics Inc (NASDAQ:MRNA) and Bayer AG (ETR:BAYN, OTC:BAYZF), filed for a US IPO on Friday.  Foun

Covid-19 vaccine maker Moderna said 2023 product sales hit $6.7 billion, above the company's guidance, but down more than 60% from 2022.

Moderna Inc.'s stock MRNA, +2.26% was up by 1.2% after the drug maker said it sold $6.7 billion of products in 2023. Analyst expected the company to sell $6.35 billion in products in 2023.

Moderna on Monday reported preliminary 2023 sales of $6.7 billion for its COVID vaccine, surpassing the lower end of its full-year forecast, while reiterating its goal of returning to sales growth in

Moderna's sales show the steep drop in demand for Covid products as cases and public concern about the virus dwindled front their pandemic peaks.